FiercePharmaOriginal article
{"a":[{"_":"Fierce Pharma Asia—Legend’s first profit; Taiho, Cullinan’s EGFR win; WuXi AppTec’s reprieve","$":{"href":"/pharma/legend-first-profit-taiho-cullinan-egfr-win-wuxi-apptec-reprieve","hreflang":"en"}}]}
Phase 3positiveCarvyktiEGFR candidatePositive
AI Analysis
Summary
Legend Biotech achieved profitability while advancing Carvykti, and Taiho/Cullinan's EGFR candidate met Phase 3 endpoints. WuXi AppTec secured a preliminary injunction against a Defense Department black list designation.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Taiho and Cullinan's EGFR candidate delivered a phase 3 win
Importance:6/10
Sentiment:
0.70
profitabilityPhase 3 dataEGFRlegal victoryCAR-T
Read the original article
Published by FiercePharma on August 13, 2026 9:27 PM